Aurobindo Pharma Limited (AUROPHARMA) share price and analysis
AUROPHARMA last traded at ₹1,794.10 (+0.01%) on the NSE. Market cap ₹1,03,229 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 8.1/10 (Excellent)
- Valuation: 8.3/10
- Profitability: 6.1/10
- Growth: 10.0/10
- Financial health: 6.8/10
- Price trend: 9.3/10
Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of AUROPHARMA
- Valuation (P/E) (P/E 26.0 vs sector 41.1): Trades about 37% below its sector's median P/E, so it's cheaper than peers. Make sure growth isn't the reason.
- Long-term trend (+20.3% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- Revenue growth (YoY) (+23.9%): Sales are growing fast.
- Profit growth (YoY) (+33.9%): Profits are growing rapidly.
- 50-DMA vs 200-DMA (+13.6% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- Price vs growth (PEG) (PEG 0.77): Price looks cheap for how fast profits are growing.
- Debt / equity (0.22): Comfortable debt level.
- Momentum (RSI 14) (RSI 61): Strong bullish momentum without being overbought.
- Net profit margin (10.8%): Healthy profit margins.
- 6-month performance vs Nifty 50 (+18.7% vs +7.4%): Outperforming the Nifty 50.
- 52-week range (4% below high): Trading near its 52-week high, so buyers are in control.
- Current ratio (1.73): Comfortable liquidity.
- Volatility (1Y) (27% annualised): Below-average volatility.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 26.0 | Cheaper than peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 18.7 | Profits expected to grow | below today's P/E (26.0) and near 41 |
| Price / book | 2.62 | Normal | 2–6 |
| EPS (TTM) | ₹69.05 | Profitable | above ₹0 |
| Return on equity | 10.7% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.22 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 10.8% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 15.5% | Average | 20%+ strong, below 10% thin |
| Revenue growth | +23.9% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | +33.9% | Growing well | 10%+ a year (falling is weak) |
| Dividend yield | 0.78% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.73 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹1,859.90 | 4% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹1,106.00 | Price is 62% above it | |
| 50-DMA | ₹1,693.33 | Price 6.0% above | price above it = short-term uptrend |
| 200-DMA | ₹1,490.95 | Price 20.3% above | price above it = long-term uptrend |
| 1Y return | +59.6% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.02 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 54.8% | Owners have a big stake | 50%+ shows owner commitment |
| Institutions | 29.7% | Moderate interest | 30%+ is strong |
| Analyst target | ₹1,870.67 | 4.3% upside · 27 analysts | 8%+ upside |
Questions about AUROPHARMA
What is the share price of Aurobindo Pharma Limited (AUROPHARMA) today?
AUROPHARMA last traded at ₹1,794.10 (+0.01% on the day) on the NSE. Its 52-week range is ₹1,106.00 to ₹1,859.90. Prices are delayed and come from Yahoo Finance.
Is AUROPHARMA a good stock for the long term?
StockLens rates AUROPHARMA 8.1 out of 10 (Excellent) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: cheap vs peers, uptrend, revenue growth.
Is AUROPHARMA share overvalued?
AUROPHARMA trades at a P/E of 26.0 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 2.62.
Is AUROPHARMA good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 20.3% above its 200-day average and 14-day RSI is 61.
Which stocks are similar to AUROPHARMA?
Similar Pharma & Healthcare stocks of comparable size include Max Healthcare, Cipla, Dr. Reddy's Laboratories, Lupin, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Stocks similar to AUROPHARMA
- Max Healthcare share price
- Cipla share price
- Dr. Reddy's Laboratories share price
- Lupin share price
- Zydus Lifesciences share price
- Apollo Hospitals share price
Compare AUROPHARMA with MAXHEALTH, CIPLA, DRREDDY
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.